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ABSTRACT
Guillain-Barré syndrome (GBS) is an autoimmune-mediated peripheral neuropathy 
of unknown cause. However, about a quarter of GBS patients have suffered a recent 
bacterial or viral infection, and axonal forms of the disease are especially common 
in these patients. Proteomics is a good methodological approach for the discovery 
of disease biomarkers. Until recently, most proteomics studies of GBS and other 
neurodegenerative diseases have focused on the analysis of the cerebrospinal fluid 
(CSF). However, serum represents an attractive alternative to CSF because it is easier 
to sample and has potential for biomarker discovery. The goal of this research was the 
identification of serum biomarkers associated with recovery from GBS. To address this 
objective, a quantitative proteomics approach was used to characterize differences in 
the serum proteome between a GBS patient and her healthy identical twin in order to 
lessen variations due to differences in genetic background, and with additional serum 
samples collected from unrelated GBS (N = 3) and Spinal Cord Injury (SCI) (N = 3) 
patients with similar medications. Proteomics results were then validated by ELISA 
using sera from additional GBS patients (N = 5) and healthy individuals (N = 3). All 
GBS and SCI patients were recovering from the acute phase of the disease. The results 
showed that Piccolo, a protein that is essential in the maintenance of active zone 
structure, constitutes a potential serological correlate of recovery from GBS. These 
results provided the first evidence for the Piccolo´s putative role in GBS, suggesting 
a candidate target for developing a serological marker of disease recovery.
INTRODUCTION
Guillain-Barré syndrome (GBS) is an immune-
mediated peripheral neuropathy that has been identified 
as the main cause of the acute neuromuscular paralysis, 
with an annual incidence ranging from 0.81 to 1.89 
cases per 100.000 people [1, 2]. GBS is characterized 
by rapidly evolving ascending weakness, mild sensory 
loss and hyporeflexia or areflexia, progressing to a 
nadir over up to four weeks [2]. Besides the classic 
presentation of ascending paralysis in demyelinating GBS, 
different subtypes of GBS such as Acute Inflammatory 
Demyelinating Polyneuropathy (AIDP), Miller Fisher 
Syndrome (MFS), Acute Motor Axonal Neuropathy 
(AMAN), Acute Motor Sensory Axonal Neuropathy 
(AMSAN), Acute Panautonomic Neuropathy and 




Although GBS is considered to be an autoimmune 
disease with the involvement of both cellular and humoral 
immune responses [2], the precise cause of the syndrome 
is unknown [2, 5-9]. About a quarter of patients with 
GBS have suffered a recent bacterial or viral infection, 
and axonal forms of the disease are especially common 
in these patients [2, 10-14]. Recent results showed that 
infection leads to antibody production, which cross-reacts 
with gangliosides and other glycolipids leading to myelin 
destruction by complement activation or by antibodies 
targeting macrophages via the Fc receptor and leading to 
both demyelination and nerve conduction failure [2, 14]. 
Furthermore, recent results point at pathogen-derived 
proteins as triggers of molecular mimicry involved in the 
GBS [15-17].
The post-genomic or “omics” technologies allow 
a high throughput analysis of cell, tissue or organism 
response to different conditions, thus improving our 
understanding of the biological processes involved and the 
possibilities for the identification of targets for prognosis, 
therapeutic and preventive interventions. However, few 
studies have applied “omics” technologies to the study of 
GBS. Recently, we used a transcriptomics approach for 
the identification of biomarkers associated with recovery 
from GBS [18]. The results showed the presence of up- 
and down-regulated transcripts in response to GBS in 
these patients when compared to matching healthy control 
individuals. These results identified new biomarkers 
associated with GBS recovery and suggested that early 
growth response gene-2 (EGR2) over-expression has a 
pivotal role in the down-regulation of cytokines implicated 
in the pathophysiology of this acute neuropathy [18]. At 
the protein level, few studies have applied proteomics 
for the characterization of the cerebrospinal fluid (CSF) 
proteome in GBS patients (see for example [19-21]). 
However, the serum proteome has been only partially 
characterized in patients with GBS and could be a source 
of potential biomarkers for this disease [22].
Treatment strategies for patients with GBS 
include plasmapheresis, intravenous immunoglobulin 
administration and immunosuppressive drugs [2, 4]. 
However, new diagnosis and treatment strategies are 
necessary to prevent both the development of the 
syndrome as well as the persistent disability in GBS 
patients [4]. The results of previous studies showed the 
possibilities of “omics” technologies for the study of GBS 
[15-19]. A better understanding of the immunological and 
pathological mechanisms involved in GBS is essential 
for the development of new treatments. Additionally, 
molecular studies of GBS using high throughput 
technologies such as proteomics may result in the 
identification of new predictors and disease biomarkers. 
The goal of the research reported here was the 
identification of potential serological biomarkers 
associated with the GBS. To address this objective, a 
quantitative proteomics approach was used to characterize 
differences in the serum proteome between GBS patients, 
unrelated Spinal Cord Injury (SCI) patients with similar 
medications and healthy individuals. The results suggested 
that Piccolo might be a serological correlate of recovery 
from GBS.
RESULTS AND DISCUSSION
Serum proteome in GBS patients reveals Piccolo 
protein as a candidate serological correlate of 
recovery from GBS
Until recently, most proteomics studies of GBS 
and other neurodegenerative diseases such as multiple 
sclerosis have focused on the analysis of the CSF [19-21, 
23]. However, while the CSF might be considered more 
tissue specific, patients sample collection is invasive and 
poses risks that range from headache to nerve damage and 
paraplegia, therefore resulting unacceptable for regular 
sampling [24]. Serum represents an attractive alternative 
to CSF because it is easier to sample and has potential 
for biomarker discovery [22, 25]. Although serum lacks 
tissue specificity and reflects the protein content of various 
tissues and cell types, serum proteomics studies should be 
successful if based on groups of well-phenotyped patients 
[23-25]. 
Our study was based on well-defined GBS and 
unrelated SCI patients on similar medications, and 
healthy control individuals [18]. Data on patients and 
control individuals were described in detail in [18] and 
summarized in Table 1. The proteomics analysis was 
conducted with serum samples collected from a GBS 
patient (A3) and her healthy identical twin (B3) in order to 
reduce variations due to differences in genetic background 
[18], and with additional serum samples collected from 
unrelated GBS (N = 3; AI-AIII) and SCI (N = 3; DI-DIII) 
patients with similar medications (Table 1). Serum samples 
were collected simultaneously from the patient and her 
control healthy twin at conclusion of the locomotion 
rehabilitation program when the patient was close to be 
discharged from the hospital, and when differences at the 
transcriptomics level were identified between the GBS 
patient and her healthy identical twin [18]. The remaining 
GBS and SCI patients were also recovering from the acute 
phase of the disease (Table 1). Pairwise comparisons were 
done between iTRAQ proteomics data from all samples to 
select differentially represented proteins selected with 1% 
FDR (Figure 1). 
A total of 330 proteins were quantified in all 
samples (Supplemental Table S1), and of them 14 were 
differentially represented after pairwise comparisons 
between different groups (Figure 1 and Supplemental 
Table S1). The GBS-related response showed the 
differential representation of secreted proteins included 
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in biological processes involved in GBS and other 
neuropathies, therefore suggesting their role in disease 
progression and recovery [16, 26-32] (Figure 2A-
2C). However, the only protein that was differentially 
represented in GBS patients when compared to SCI 
patients (AI-AIII vs. DI-DIII) and healthy individual (B3 
vs. AI-AIII), and not affected by comparison between 
GBS patients (A3 vs. AI-AIII), SCI patients and healthy 
individual (B3 vs. DI-DIII), or between identical twins 
(A3 vs. B3, which may reflect A3-specific response) was 
Piccolo (Figure 1). The fact that Piccolo serum protein 
levels did not differ between GBS (A3) and healthy (B3) 
identical twins or between A3 and GBS patients (AI-
AIII), but differed between B3 and GBS patients (AI-AIII) 
precluded the existence of an A3-individual rather than a 
GBS group-associated response, which may be possible to 
identify in individuals with identical genetic background. 
Therefore, the Piccolo protein that was over-represented 
in GBS patients recovering from the acute disease phase 
(Figure 2A), was selected as a potential serological 
correlate of recovery from GBS.
Validation of proteomics results confirm the 
potential of Piccolo as a serological correlate of 
recovery from GBS
For validation of proteomics results, a Piccolo 
ELISA was performed using sera from GBS (N = 8; A3, 
AI-AVII) and SCI (N = 4; DI-DIV) unrelated patients on 
similar medications, and healthy control individuals (N 
= 4; B3, CI-CIII), including the GBS patient (A3) and 
Table 1: Summary of GBS and SCI patients, and healthy individuals included in the study.
Identification Individual Clinical diagnosis Age Gender Functional status
A3 GBS patient twin
GBS,
AMSAN variant 23 F Able to stand and walk with help
AI GBS patient I GBS ,AMAN variant 31 M
Generalized muscle atrophy of 4 limbs, able 
to stand, wheelchair-bound for displacements, 
dysphagia, dysarthria
AII GBS patient II GBS,Undetermined variant 84 F
Wheelchair-bound, lack of voluntary movements 
on 4 limbs
AIII GBS patient III GBS , AMAN variant 68 M Able to stand and walk short distances with help, wheelchair for long displacements
AIV GBS patient IV GBS,AMAN variant 70 M
Able to perform daily basic activities with help, 
stands and walks with gaitaid walker device
AV GBS patient V GBS,AMAN variant 54 M
Wheelchair bound for displacements, able to 
stand short periods, with help
AVI GBS patient VI GBS,AMAN variant 71 F
Mild tetraparesia, able to stand and walk short 
distances with help, able to perform basic daily 
activities with help
AVII GBS patient VII GBS,Undetermined variant 55 F
Able to perform basic daily activities, stands and 
walks with gaitaid walker device
DI SCI patient I SCIat cervical  level 7 64 M
Complete paraplegia, wheel chair for any 
displacement
DII SCI patient II SCIat cervical  level 4 56 M Tetraplegic, wheelchair-bound
DIII SCI patient III SCIat cervical  level 4 44 M Tetraplegic, wheelchair-bound
DIV SCI patient IV SCIat cervical  level 5 51 F
Incomplete tetraplegia, able to stand with help, 
wheelchair-bound fordisplacements
B3 Control healthy twin Healthy 23 F Healthy
CI Control healthy individual I Healthy 30 F Healthy
CII Control healthy individual II Healthy 41 F Healthy
CIII Control healthy individual III Healthy 55 M Healthy
GBS patients (N = 8; A3, AI-AVII), SCI unrelated patients (N = 4; DI-DIV), and healthy individuals (N = 4; B3, Ci-CIII) were 
included in the study. GBS patients were sampled after recovering from the acute disease phase with similar medications. 
Medications are described in [18]. Abbreviations: GBS, Guillain-Barré syndrome; SCI, Spinal Cord Injury; AMSAN, Acute 
Motor Sensory Axonal Neuropathy; AMAN, Acute Motor Axonal Neuropathy; F, female; M, male.
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her healthy identical twin (B3) (Table 1). The results 
of the ELISA corroborated the proteomics results by 
showing higher Piccolo protein concentration in sera 
from GBS patients when compared to SCI patients and 
healthy individuals (Figure 3A). These results were 
similar when performing the analysis only with GBS 
patients (AIV-AVII) and healthy individuals (CI-CIII) not 
included in the proteomics analysis (Figure 3B), therefore 
providing support with an independent set of samples 
for the potential of Piccolo as a serological correlate of 
recovery from GBS. Additionally, a negative correlation 
was obtained between Piccolo serum levels and patient 
functional status (Table 1), suggesting again an increase in 
Piccolo serum levels during disease recovery (Figure 3C).
Antibodies against single ganglioside species 
remain the most established serological marker of GBS 
[33]. Recently, ELISA for the detection of antibodies 
against combinations of gangliosides and ganglioside-
complex antibodies have emerged as a new method for 
the diagnostic of certain GBS variants, but do not seem to 
greatly improve the diagnosis of GBS [33]. Therefore, new 
serum markers are needed for better GBS diagnosis. The 
results of our study confirmed the potential of Piccolo as a 
serological correlate of recovery from GBS, and supported 
the conduction of additional experiments to validate its 
application as a serum marker for GBS.
Piccolo´s putative role during GBS
Piccolo is a high molecular weight active zone 
specific scaffolding protein that is essential in the 
maintenance of active zone structure [34, 35]. This 
protein is involved in assembling presynaptic F-actin, 
gathering synaptic vesicles, and controlling synaptic 
Figure 1: Differentially represented serum proteins. Serum samples collected from a GBS patient (A3) and her healthy identical 
twin (B3) [18], and from unrelated GBS (N = 3; AI-AIII) and SCI (N = 3; DI-DIII) patients with similar medications were included in the 
proteomics analysis (Table 1). The 5% FDR was used as criterion for peptide identification. Protein identification (Uniprot accession) and 
name are shown. For over-represented and under-represented protein quantifications, a standardized variable of protein fold changes was 
used (Zq), where statistical significance of protein abundance changes was considered using a 1% FDR. 
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transmission and voltage-gated calcium channel function 
[34, 35]. Piccolo is involved in multiple protein-protein 
interactions [35] and functional associations (Figure 
4A). These interactions result in a role for Piccolo in 
multiple biological processes such as regulation of 
exocytosis, synapse assembly and function, insulin 
secretion, regulation of neurotransmission, cytoskeleton 
organization, and sensory perception (Figure 4B) affecting 
both central and peripheral nervous systems [35-37]. 
Additionally, Piccolo has been localized not only at cell 
junctions and cytoskeleton, but also in the extracellular 
exosome from human neural stem cells [38]. 
The presynaptic neuromuscular junction (NMJ) 
has been considered a potential target vulnerable to 
autoimmune attack in GBS and related diseases [2, 3, 10-
16]. Therefore, Piccolo may be involved in recovering 
from GBS by reinstalling the activity of the presynaptic 
active zone [35, 39, 40], which helps restoring movement 
and function to a person’s full potential [2, 3]. The 
increase in serum Piccolo levels observed in GBS patients 
during recovery from the acute phase of the disease may 
reflect protein secretion during molecular remodeling of 
the presynaptic active zone. This finding needs additional 
experiments using animal models (i.e. [39-41]) in order to 
characterize the role of Piccolo in the recovery from GBS, 
providing additional support for the results presented here. 
In summary, using a quantitative serum proteomics 
approach we have shown that Piccolo constitutes a 
potential serological correlate of recovery from GBS. 
These results need to be validated using a larger number 
of GBS patients and animal models, but provided the 
first evidence for the Piccolo´s putative role during GBS, 
suggesting a candidate target for developing a serological 
marker for disease recovery. 
MATERIALS AND METHODS
Ethics statement
The use of human material, including peripheral 
blood serum samples from GBS patients, SCI patients 
and healthy individuals was approved by the Clinical 
Figure 2: GBS-related serological response. A. Differentially represented proteins were grouped as under-represented and over-
represented in GBS patients when compared to SCI patients or healthy twin. Protein ontology analysis for biological process was done 
using the Blast2GO software (www.blast2go.com) for B. under-represented and C. over-represented proteins.
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Figure 4: Piccolo-protein interactions. A. STRING was used for the in silico characterization of Piccolo-protein interactions using a 
high confidence interaction score (0.700; http://bit.ly/2anoqgi). Each node represents all the proteins produced by a single protein-coding 
gene locus. Protein-protein associations represent proteins that jointly contribute to a shared function, but not necessarily physically bind to 
each other. B. Protein ontology analysis for biological process was done for Piccolo and interacting proteins using the Blast2GO software 
(www.blast2go.com).
Figure 3: Piccolo as a potential serological correlate of recovery from GBS. Sera from GBS (N = 8; A3, AI-AVII) and SCI (N 
= 4; DI-DIV) unrelated patients with similar medications, and healthy control individuals (N = 4; B3, CI-CIII), including the GBS patient 
(A3) and her healthy identical twin (B3) were included in the ELISA (Table 1). ELISA plates were coated with 100 μl/well of albumin-
depleted sera at concentration of 2 ng/μl (0.2 μg serum/well). Mouse monoclonal anti-Piccolo antibodies were added at 1:1000 dilution and 
detected using anti-mouse IgG (μ-chain specific)-peroxidase antibodies produced in goat. Color was developed by the addition of TMB to 
measure the OD450 nm. For Piccolo protein quantitation, the human recombinant protein was used. Two technical replicates were included 
for each sample. The Piccolo concentration in serum samples was compared between GBS patients, SCI patients and healthy individuals 
by Student´s t-test with unequal variance (P = 0.05). A. Piccolo serum levels in GBS (N = 8; A3, AI-AVII) patients, SCI (N = 4; DI-DIV) 
unrelated patients, and healthy control individuals (N = 4; B3, CI-CIII). B. Piccolo serum levels determined in GBS patients (AIV-AVII) 
and healthy individuals (CI-CIII) not included in the proteomics analysis. C. Negative correlation between Piccolo serum levels and patient 
functional status (Table 1). Correlation coefficient (R2) is shown.
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Research Ethics Committee for Hospitals of Toledo City 
(permit No. 17), and informed consent was obtained 
from all individuals in compliance with the Helsinki 
Declaration. Blood samples of patients and controls were 
extracted by nursing personnel to patients and controls in 
the Paraplegics National Hospital (Toledo, Spain). 
Serum samples
For separation of serum from the total blood a sterile 
tube without anticoagulant was used. The blood from each 
individual (5 ml) was maintained in standing position 
at room temperature (RT) for clotting (20-30 min), and 
centrifuged at 1500 x g for 20 min at RT. Serum was 
collected and conserved at -20 ºC until used for cytokine 
protein analysis.
Proteomics data acquisition and analysis 
Serum samples collected from a GBS patient 
(A3) and her healthy identical twin (B3) [18], and from 
unrelated GBS (N = 3; AI-AIII) and SCI (N = 3; DI-
DIII) patients with similar medications were included 
in the analysis (Table 1). The protein extracts (100 μg 
serum from each patient), were suspended in 50 μl of 
sample buffer and applied onto 1.2-cm wide wells of 
a conventional SDS-PAGE gel (0.75 mm-thick, 4% 
stacking, and 10% resolving). Then run was stopped as 
soon as the front entered 3 mm into the resolving gel, 
so that the whole proteome became concentrated in the 
stacking/resolving gel interface. The unseparated protein 
bands were visualized by Coomassie staining, excised, cut 
into cubes (2 mm3), and placed in 0.5 ml microcentrifuge 
tubes. The gel pieces were destained in acetonitrile:water 
(ACN:H2O, 1:1). Disulfide bonds from cysteinyl residues 
were reduced with 10 mM DTT for 1 h at 56 ºC, and then, 
thiol groups were alkylated with 50 mM iodoacetamide 
for 1 h at room temperature in darkness. Proteomes were 
finally digested in situ with sequencing grade trypsin 
(Promega, Madison, WI) as described by Shevchenko et 
al. [42] with minor modifications. The gel pieces were 
shrunk by removing all liquid using sufficient acetonitrile, 
which was pipetted out and the gel pieces were dried in 
a speed-vac. The dried gel pieces were re-swollen in 50 
mM ammonium bicarbonate pH 8.8 with 60 ng/ml trypsin 
at 5:1 protein:trypsin (w/w) ratio. The tubes were kept in 
ice for 2 h and incubated at 37°C for 12 h. Digestion was 
stopped by the addition of 1% TFA. Whole supernatants 
were dried down and then desalted onto OASIS HLB 
Extraction Cartridges (Waters Corporation, Mildford, 
MA, USA) until the iTRAQ labeling. The resultant 
peptide mixture from proteins tryptic digest was labeled 
using chemicals from the iTRAQ reagent 8plex Multi-plex 
kit (reagents 113, 114, 115, 116, 117, 118, 119 and 121) 
(Applied Biosystems, Foster City, CA, USA) essentially 
as described by Köcher et al. [43]. Briefly, peptides 
were dissolved in 0.5 M triethylammonium bicarbonate 
(TEAB), adjusted to pH 8. For labeling, each iTRAQ 
reagent was dissolved in 50 μL of isopropanol and added 
to the respective peptide mixture and then incubated at 
room temperature for two hours. Labelling was stopped 
by the addition of 0.1% formic acid. Whole supernatants 
were dried down and the eight samples were mixed to 
obtain the “8plex-labeled mixture”. The mixture was 
desalted onto OASIS HLB Extraction Cartridges (Waters 
Corporation) until the mass spectrometric analysis. The 
desalted 8plex-labeled mixture was dried, resuspended in 
10 l of 0.1% formic acid and analyzed by reverse phase 
liquid chromatography coupled to mass spectrometry (RP-
LC-MS/MS) in an Easy-nLC II system coupled to an ion 
trap LTQ-Orbitrap-Velos-Pro mass spectrometer (Thermo 
Scientific). The peptides were concentrated (on-line) by 
reverse phase chromatography using a 0.1mm × 20 mm 
C18 RP precolumn (Proxeon), and then separated using a 
0.075mm x 250 mm C18 RP column (Proxeon) operating 
at 0.3 μl/min. Peptides were eluted using a 240-min dual 
gradient from 5 to 25% solvent B in 180 min followed 
by gradient from 25 to 40% solvent B over 240 min 
(Solvent A: 0,1% formic acid in water, solvent B: 0,1% 
formic acid, 80% acetonitrile in water). ESI ionization was 
done using a Nano-bore emitters Stainless Steel ID 30 μm 
(Proxeon) interface. The instrument method consisted 
of a data-dependent top-20 experiment with an Orbitrap 
MS1 scan at a resolution (m/Δm) of 30,000 followed by 
either twenty high erenergy collision dissociation (HCD) 
MS/MS mass-analyzed in the Orbitrap at 7,500 (Δm/m) 
resolution. MS2 experiments were performed using HCD 
to generate high resolution and high mass accuracy MS2 
spectra. The minimum MS signal for triggering MS/MS 
was set to 500. The lock mass option was enabled for both 
MS and MS/MS mode and the polydimethylcyclosiloxane 
ions (protonated (Si(CH3)2O))6; m/z 445.120025) were 
used for internal recalibration of the mass spectra. 
Peptides were detected in survey scans from 400 to 1600 
amu (1 μscan) using an isolation width of 2 u (in mass-to-
charge ratio units), normalized collision energy of 40% 
for HCD fragmentation, and dynamic exclusion applied 
during periods of 30 seconds. Precursors of unknown or 
+1 charge state were rejected.
The raw files were analyzed using Thermo Proteome 
Discoverer 1.4, with a Uniprot database containing 
147.854 entries of Homo sapiens (September 8, 2015). 
For database searching, parameters were selected as 
follows: trypsin digestion with 2 maximum missed 
cleavages, precursor mass tolerance 800 ppm, fragment 
mass tolerance of 0.05 Da, allowing variable modifications 
methionine oxidation, cysteine carbamidomethylation, 
and lysine oTRAQ 8-plex (of +304.205 Da), and fixed 
modification of peptide N-terminus for iTRAQ 8-plex. The 
same MSMS spectra were also searched against inverted 
databases constructed from the same target databases. 
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Peptide identification from MSMS data was performed 
using the probability ratio method [44]. False discovery 
rates (FDR) of peptide identifications were calculated 
using the refined method [45, 46], and 5% FDR was 
used as criterion for peptide identification. Each peptide 
was assigned only to the best protein proposed by the 
Proteome Discoverer algorithm. Quantitative information 
was extracted from MS/MS spectra using a quantitative 
proteomics software package (QuiXoT) [47], and protein 
abundance changes were analyzed using the Generic 
Integration Algorithm [48]. Calculation of statistical 
weights of each quantitation at the spectrum level was 
performed according to the WSPP model [47]. The validity 
of the null hypothesis at each one of the levels (spectrum, 
peptide, and protein) was carefully checked by plotting 
the cumulative distributions of the standardized variables 
for each level (Zs, Zp and Zq), which were calculated as 
a function of the corresponding fold-changes (Xs, Xp and 
Xq) and the corresponding general variances (s2s, s2p and 
s2q). Statistical significance of outliers (at spectrum and 
peptide levels) and expression changes (at protein level) 
were considered using the calculated FDR values [47].
Piccolo ELISA
Sera from GBS (N = 8; A3, AI-AVII) and SCI (N = 
4; DI-DIV) unrelated patients with similar medications, 
and healthy control individuals (N = 4; B3, CI-CIII), 
including the GBS patient (A3) and her healthy identical 
twin (B3) were included in the analysis (Table 1). Sera 
were albumin depleted with Pierce albumin depletion 
Kit (Thermo Scientific, San Jose, CA, USA) following 
manufacturer’s instructions. ELISA plates were coated 
with 100 μl/well of albumin-depleted sera at concentration 
of 2 ng/μl in carbonate/bicarbonate buffer and incubated 
overnight at 4 °C. Then, 100 μl of blocking buffer (5% 
skim milk powder in phosphate buffered saline, PBS) were 
added to each well and incubated 1 hr at room temperature 
(RT) followed by five washes with PBS supplemented with 
0.05% Tween 20 (PBST) (Sigma-Aldrich, Madrid, Spain). 
The mouse monoclonal anti-human Piccolo antibodies 
[6H9-B6] (ab101654; Abcam, Cambridge, UK), which 
are specific for human Piccolo and without cross-reactivity 
to Bassoon (http://www.abcam.com/piccolo-antibody-
6h9-b6-ab101654-references.html) were added at 1:1000 
dilution and incubated for 1 hr at 37 °C followed by five 
washes with PBST. For the detection of Piccolo, 100 μl of 
anti-mouse IgG (μ-chain specific)-peroxidase antibodies 
produced in goat (Sigma-Aldrich) were added at a 
1:1000 dilution in blocking buffer. Plates were incubated 
for 1h at RT, and subsequently washed with PBST five 
times. Color was developed by the addition of 100 μl of 
3,3′,5,5′-tetramethylbenzidine (TMB) (Promega Biotech, 
Madrid, Spain) and protected from the light for 20 min at 
RT. The optical densities (OD) were measured at 450 nm 
with an ELISA reader. The average value of the blanks 
(wells without serum coating; N = 4) was subtracted from 
all reads. For Piccolo protein quantitation, the human 
recombinant protein (Abnova, Taipei, Taiwan) was used as 
standard. Two technical replicates were included for each 
sample. The Piccolo concentration in serum samples was 
compared between GBS patients, SCI patients and healthy 
individuals by Student´s t-test with unequal variance (P = 
0.05).
Protein-protein interactions and protein ontology 
annotation
STRING (version 10.0; http://version_10.string-
db.org/) was used for the in silico characterization of 
Piccolo-protein interactions [49] using a high confidence 
interaction score (0.700; http://bit.ly/2anoqgi). Protein 
ontology analysis for biological process was done using 
the Blast2GO software (www.blast2go.com). 
Data availability
The iTRAQ mass spectrometry proteomics data are 
available from the PeptideAtlas available at http://www.
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